CTRI/2020/06/025854Active, not recruiting未知
Study to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1)Elderly individuals 60 years â?? 95 years of age with general good health, as confirmed by history and physical examination.
- •2) No known history of HIV or on immunosuppressive drugs for malignancy or transplant
- •3) Provide a signed and dated informed consent form
- •Elderly individuals with or without co-morbid conditions like Diabetes mellitus, or Hypertension or Hyperlipidemia will be considered for this study, if they are on regular treatment.
Exclusion Criteria
- •1) Positive for SARS-Cov2 infection, by either antibody (serology) or PCR test
- •2) Known HIV or malignancy or Transplant recipient or on Dialysis
- •3) Individuals on immune-suppressive therapies or treatments for malignancy or transplant / dialysis / anti-retroviral treatment
- •4) Recently (in the last 6-months) diagnosed with TB or currently on anti-TB treatment or anti-psychiatric medications
- •5) Has any BCG vaccine contraindication like allergy or hypersensitivity to BCG, individuals with HIV infection, leukaemia, malignant lymphoma, chronic granulomatous disease,
- •6) H/o of previous administration of experimental MTB vaccines within the past 6 months.
- •7) Sick and moribund individuals with Karnofsky score <50
Investigators
Similar Trials
Recruiting
Phase 2
Effect of BCG in treatment of diabetes type 1IRCT20201012049003N1Yazd University of Medical Sciences16
Active, not recruiting
Phase 1
Safety and effectivity of BCG vaccination against controlled human malaria infectioPlasmodium faciparum malaria preventionMedDRA version: 18.1Level: LLTClassification code 10036655Term: Prevention of malariaSystem Organ Class: 100000004865MedDRA version: 18.1Level: PTClassification code 10025487Term: MalariaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: LLTClassification code 10016171Term: Falciparum malariaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-005735-40-NLRadboud university medical center
Completed
Phase 2
Safety and protective efficacy of BCG vaccination against controlled human malaria infectioPlasmodium falciparum10037072malariaNL-OMON43394Radboud Universitair Medisch Centrum20
Recruiting
Phase 3
Effect of BCG Vaccine on Preventing COVID-19Coronavirus Disease 2019 (COVID-19).U07.1 COVID-19, virus identifiedU07.1 COVIIRCT20200411047019N1Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Mdical Sciences500
Completed
Phase 1
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult VolunteersPulmonary TuberculosisNCT01927159Access to Advanced Health Institute (AAHI)66